Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STARTVerso 3: Faldaprevir + PegIFN/RBV in Treatment-Experienced Chronic HCV GT-1
NCT01358864Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2011
- Primary completion
- Feb 2013
- Modality
- Small Molecules, Modified Peptides
- Countries
- 12
01
Overview
A Phase 3 trial of faldaprevir in hepatitis C (HCV), sponsored by Boehringer Ingelheim. Started Jun 2011; status: completed.
02
Drugs
faldaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01358864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01358864.